Who is winning the GLP-1 race? For investors, massive sales of blockbuster drugs like Ozempic aren’t enough; they’re thinking about what’s coming next. A stock rally or dip is now more likely to be triggered by trial results for the new GLP-1 drugs in their pipeline than strong sales numbers. See this chart of many GLP-1 drugs in trial phases, including where they are in the process and how the weight loss compares with the drugs on the market. #Data is beautiful sherwood.news/business/wh..